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Abstract
Background: Caused by Mycobacterium leprae (ML), leprosy presents a strong immune-inflammatory component,
whose status dictates both the clinical form of the disease and the occurrence of reactional episodes. Evidence has
shown that, during the immune-inflammatory response to infection, the growth hormone/insulin-like growth
factor-I (GH/IGF-I) plays a prominent regulatory role. However, in leprosy, little, if anything, is known about the
interaction between the immune and neuroendocrine systems.
Methods: In the present retrospective study, we measured the serum levels of IGF-I and IGBP-3, its major binding
protein. These measurements were taken at diagnosis in nonreactional borderline tuberculoid (NR BT), borderline
lepromatous (NR BL), and lepromatous (NR LL) leprosy patients in addition to healthy controls (HC). LL and BL
patients who developed reaction during the course of the disease were also included in the study. The serum
levels of IGF-I, IGFBP-3 and tumor necrosis factor-alpha (TNF-a) were evaluated at diagnosis and during
development of reversal (RR) or erythema nodosum leprosum (ENL) reaction by the solid phase, enzyme-labeled,
chemiluminescent-immunometric method.
Results: The circulating IGF-I/IGFBP-3 levels showed significant differences according to disease status and
occurrence of reactional episodes. At the time of leprosy diagnosis, significantly lower levels of circulating IGF-I/
IGFBP-3 were found in NR BL and NR LL patients in contrast to NR BT patients and HCs. However, after treatment,
serum IGF-I levels in BL/LL patients returned to normal. Notably, the levels of circulating IGF-I at diagnosis were
low in 75% of patients who did not undergo ENL during treatment (NR LL patients) in opposition to the normal
levels observed in those who suffered ENL during treatment (R LL patients). Nonetheless, during ENL episodes, the
levels observed in RLL sera tended to decrease, attaining similar levels to those found in NR LL patients.
Interestingly, IGF-I behaved contrary to what was observed during RR episodes in R BL patients.
Conclusions: Our data revealed important alterations in the IGF system in relation to the status of the host
immune-inflammatory response to ML while at the same time pointing to the circulating IGF-I/IGFBP-3 levels as
possible predictive biomarkers for ENL in LL patients at diagnosis.
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Background
Leprosy, a chronic infectious disease caused by the obli-
gate intracellular bacterium Mycobacterium leprae (ML),
remains a major source of morbidity in developing
countries [1]. The disease principally affects the skin
and peripheral nervous system in which the leprosy
bacillus is preferentially found inside macrophages and
Schwann cells (SC) [2]. This tissue tropism causes nerve
damage, which, in turn, leads to sensorial impairment
and permanent disabilities, by far the major health con-
cerns facing leprosy patients today.
Also known as Hansen’s disease, leprosy manifests as
a spectrum of clinical forms in correlation with the nat-
ure and magnitude of the innate and adaptive immune
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extreme of the spectrum, individuals with tuberculoid
leprosy (TT) have few lesions and manifest a contained,
self-limited infection in which scarce bacilli are detected
due to the generation of a strong cellular immune
response against ML. At the other, lepromatous leprosy
(LL) is a progressively disseminating disease character-
ized by extensive bacterial multiplication within host
cells and low cell-mediated immunity (CMI) to the
pathogen. Between these two poles are the borderline
forms (characterized by their intermediate clinical and
immunological patterns), commonly referred to as bor-
derline tuberculoid (BT), borderline borderline (BB), and
borderline lepromatous (BL) in accordance with their
proximity to either one of the spectral extremes.
Nerve damage occurs in all clinical forms of the dis-
ease and may progress during multidrug therapy (MDT)
itself and even subsequent to patient release, due, for
the most part, to the occurrence of acute immune-
inflammatory episodes known as leprosy reactions. The
most frequent leprosy reactions are classified as Type 1
(reversal) reaction (RR) and Type 2 reaction, or
erythema nodosum leprosum (ENL). Many patients have
been known to experience recurrent episodes [4]. Neuri-
tis and cutaneous inflammation are prominent symp-
toms of both types of reaction with systemic
repercussions, as seen in the occurrence of malaise,
fever, and inflammation in other tissues. RR predomi-
nates in BL patients with a bacilloscopic index (BI)
below 3 while ENL occurs in LL patients with high BI
[5,6]. Over the past few decades, numerous studies have
been conducted, enhancing our knowledge of the epide-
miological, clinical, and laboratory risk factors for neu-
ropathy and reaction in leprosy. However, our
understanding of the physiopathology of reaction
remains limited so that further research is urgently
needed to more clearly define laboratory biomarkers
capable of accurately identifying the leprosy patients
most at risk of developing reaction.
The interaction between the immune and neuroendo-
crine systems plays a crucial role in host homeostasis
during the adaptive response to stress and infection
[7,8]. Indeed, an increasing understanding of how
inflammation is held under control by the neuroendo-
crine system has greatly contributed to our knowledge
of the physiopathology of several immune-inflammatory
illnesses. Furthermore, credible evidence has shown that,
during the immune-inflammatory response to infection,
the GH/IGF-I/IGFBP-3 somatotropic axis exercises a
prominent regulatory role [9]. These hormones not only
affect cellular metabolism but are likewise able to inter-
act with cytokines and glucocorticoids (GCs) in modu-
lating the immune-inflammatory response [10]. Insulin-
like growth factor-I (IGF-I) circulates in relatively high
concentration levels in plasma (150-400 ng/mL), which
varies according to age [11]. Insulin-like growth factor
binding protein-3 (IGFBP-3) binds to 80-90% of circu-
lating IGF in a stable ternary complex with an acid-
labile subunit (ALS) serving as the main reservoir for
plasma IGF-I [12]. Most of the IGF-I found in circula-
tion is produced in the liver under growth hormone
(GH) regulation.
Unfortunately, little, if anything, is known about the
interaction between the immune and neuroendocrine
systems in leprosy [13]. Since the disease has a strong
immune-inflammatory component, it is hypothesized
that the cross-talk taking place between these two sys-
tems may have a profound effect on the natural course of
ML infection. In the present investigation, a retrospective
study was conducted to compare the circulating levels of
IGF-I and IGFBP-3 across the spectral clinical forms of
leprosy in conjunction with reactional vs. nonreactional
LL and BL patients both at diagnosis and during reaction.
Our results demonstrate significant differences in circu-
lating IGF-I/IGBP-3 in leprosy according to disease sta-
tus, indicating that these proteins could be used to
identify patients at high risk of reaction.
Methods
Patients and samples
The study population consisted of 21 healthy controls
(HC) from endemic laboratory staff volunteers (3 males,
18 females, ranging in age from 19 to 62) and 93
patients (50 males, 43 females, in a 18-65 age range)
referred to the Souza Araújo Ambulatory (Reference
Center for Leprosy Diagnosis and Treatment, Oswaldo
Cruz Foundation, Rio de Janeiro, RJ, Brazil) for the diag-
nosis and treatment of leprosy. Healthy controls and
patients were carefully screened by anthropometric mea-
surements (body mass index, BMI) and biochemical
analysis; and those with diabetes, obesity or cholesterol
disorders were excluded from the study. Each patient
was assessed clinically throughout treatment and
detailed analyses of medical and dermatological exami-
nations were routinely carried out. Bacteriological exam-
inations of slit-skin smears were performed to
determine BI. The patients were categorized according
to the Ridley and Jopling’s classification scale [3] into
borderline tuberculoid (BT), borderline lepromatous
(BL), or lepromatous (LL). The diagnosis of leprosy
Type 1 reaction (RR) was determined by the appearance
of erythema and edema in either existing or new skin
lesions. The diagnosis of leprosy Type 2 reaction (ENL)
was primarily based on the acute occurrence of nodular
skin lesions, accompanied by fever with or without per-
ipheral nerve pain and/or nerve dysfunction. Nonreac-
tional (NR) groups were selected among leprosy patients
who were rendered the same histopathological
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experience reaction at initial diagnosis or during follow-
up. These NR patients were distributed into the following
groups: 13 nonreactional BT (NR BT); 19 nonreactional
BL (NR BL); 18 nonreactional LL (NR LL) patients, 25
BL who had RR during treatment (R BL); and 18 LL who
developed ENL during treatment (R LL). Blood was col-
lected at three different time points: i) at the beginning of
leprosy treatment, ii) at diagnosis of a reactional episode
if one occurred; and iii) 3-5 years post-treatment. Blood
samples were taken from 1995 to 2005; and patient sera
were extracted and stored at -20°C until retrieval for ana-
lysis. The baseline characteristics of each group of indivi-
duals included in the study are shown in Table 1.
Patients received World Health Organization-recom-
mended leprosy multidrug therapy (MDT). Reactions
were treated with prednisolone, starting at 40 mg/day,
and gradually tapering off over a 12-week period.
Ethical considerations
This study was approved by the Ethics Committee of
the Oswaldo Cruz Foundation. Informed written con-
sent was obtained from all patients or their guardians
and the healthy controls prior to specimen collection.
IGF-I, IGFBP-3, and TNF-a measurement
The serum levels of IGF-I, IGFBP-3, and TNF-a were
measured by the IMMULITE 2000 Analyzer (EuroDPC
Med Limited, Llanberis, UK). Assays were carried out
using the solid phase, enzyme-labeled, chemilumines-
cent-immunometric method in accordance with the
manufacturer’s instructions. IGF-I and IGFBP-3 levels
were considered normal according to the reference
range by age provided by the kit manufacturer [14].
Statistical analysis
Data are expressed as median, mean ± S.D. values.
Group comparisons were evaluated by the analysis of a
variance (ANOVA) test, using age as a covariate, fol-
lowed by Bonferroni’s test for multiple comparisons.
Paired t test was employed to compare IGF-I, IGFBP3,
and TNF-a levels before and during reaction. Pearson
partial correlation coefficient (controlled for age) was
calculated between BI and IGF-I and IGFBP-3 levels. All
statistical calculations were done via the SPSS software
program; and p values lower than 0.05 were considered
statistically significant.
Results
Lepromatous patients showed below-normal levels of
serum IGF-I during active disease
Evidence in the literature has shown that the somatotro-
p i ca x i si sr e s p o n s i b l ef o rm odulating the immune sys-
tem, directly influencing both the humoral and cellular
immune (CMI) responses [15,16]. Since the spectral clini-
cal forms of leprosy occur as a result of the capacity of
the host to mount anywhere from low- (LL)-to-high (TT)
CMI responses against ML, the serum levels of IGF-I and
IGFBP-3 were compared among patients having the dif-
ferent clinical forms at the pre-MDT stage. Only those
who did not undergo reactional episodes during the
course of the disease were included in this analysis, and
the levels found in leprosy patients were compared with
those of the HCs. The IGF-I levels were significantly
lower in NR BL and NR LL patients when compared to
the NR BT (P = 0.001) and HC (P < 0.001) groups (Figure
1a). A decrease in IGFBP-3 levels was also observed in
NR LL patients when compared to the NR BT (P <
0.001) and HC (P = 0.001) individuals (Figure 1b).
According to the reference range by age, 83,3% (10/12)
and 75% (12/16) of the BL and LL patients, respectively,
showed below-normal levels of serum IGF-I. Moreover,
via Pearson’s partial correlation analysis, a weak inverse
correlation was found between elevated BI and reduced
IGF-I (r = -0.56, P < 0.001) and IGFBP-3 (r = -0.47, P <
0.001) levels in these patients (data not shown).
Serum IGF-I in lepromatous patients increased reaching
normal levels after treatment
Next, to reinforce the notion that the low IGF-I levels
observed in the LL patients resulted from active modu-
lation by ML infection, their hormone levels were mea-
sured at the conclusion of MDT. Interestingly, when
serum IGF-I was evaluated in a group of nonreactional
BL/LL patients 3-5 years post-MDT treatment (n = 9),
significantly higher levels (P < 0.001) were observed in
comparison to those found in the group evaluated at
diagnosis (n = 28) (Figure 1c), with 78% of this post-
MDT nonreactional BL/LL fitting into the normal
range. Increment of serum IGF-I levels after treatment
can be clearly seen in paired pre- and post-MDT serum
samples taken from the same patient (Figure 1d).
Table 1 Baseline characteristics of leprosy patients and
healthy controls
Characteristics HC NR BT NR BL R BL NR LL R LL
Individuals (n) 21 13 19 25 18 18
Sex
Male 03 07 11 14 05 13
Female 18 06 08 11 13 05
Age (median) 36.9 35.8 42.7 39.4 37.1 37.2
(min-max) (19-63) (22-65) (19-64) (18-68) (20-62) (21-65)
Bacilloscopic Index
(median) - 0.08 1.78 1.89 4.0 4.7
Groups included in this study: HC, healthy controls; NR BT, nonreactional
borderline tuberculoid patients; NR BL, nonreactional borderline lepromatous
patients; R BL, reactional borderline lepromatous patients; NR LL,
nonreactional lepromatous patients; R LL, reactional lepromatous patients
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ENL episodes
Since the somatrotropic axis plays an important regula-
tory role during host immune-inflammatory responses
to infection, we then investigated circulating IGF-I and
IGFBP-3 levels in the context of ENL episodes. This
type of inflammatory episode occurs principally in LL
patients [6,17], the main concern being the management
of leprosy care to prevent disabilities [18]. For this pur-
pose, a group of LL patients who suffered ENL episodes
during MDT (referred to as R LL; n = 18) were enrolled
in the study. Serum samples of the R LL patients were
obtained at two different time points: i) at the onset of
MDT, at which time no signs of reaction were detected
(referred to as R LLt=0 ); and ii) during reactions
(referred to as R LLENL) taking place between 3 weeks
and 2 years after the beginning of treatment (mean aver-
age of 11.5 ± 9.3 months).
It was first investigated whether reactional LL patients
(clinically unstable patients) already display distinct levels
of IGF-I and IGFBP-3 at diagnosis in comparison to non-
reactional LL patients (a clinically stable group). Notably,
the R LLt=0samples presented significantly higher levels
of IGF-I and IGFBP-3 than the NR LL group (P <0 . 0 1 ) ,
as can be seen in Figure 2a, b, respectively. The behavior
of these proteins was subsequently monitored in the R
LL group during ENL. Interestingly, these levels
decreased dramatically (R LLENL; P < 0.05) during reac-
tion, reaching values similar to those detected in the NR
LL group, as observed in Figure 2c, d.
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Figure 1 Serum IGF-I and IGFBP-3 levels along the spectrum of leprosy clinical forms. Box-plots represent the serum levels of IGF-I (a) and
IGFBP-3 (b) assessed in healthy controls (HC) and nonreactional borderline tuberculoid patients (NR BT), borderline lepromatous leprosy patients
(NR BL), and lepromatous leprosy patients (NR LL) prior to MDT. (c) Serum levels of IGF-I of NR BL/LL patients pre-MDT and post-MDT. Median
values are indicated by lines (-). Statistical differences between the groups were evaluated by ANOVA, using age as a covariate. (d) Represent the
circulating levels of IGF-I in paired pre- and post-MDT serum samples from the same patient. Each line represents one patient.
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Page 4 of 8TNF-a was also quantified in the same serum samples
due to the well-established role of this pro-inflammatory
cytokine in ENL [19,20] along with its antagonistic
activity in IGF-I [21]. Similar range levels of TNF-a
were observed in NR LL and R LLt=0serum samples
(data not shown). However, consistent with previous
published data [19,20], TNF-a levels were higher during
ENL (P < 0.05) in comparison to those measured prior
to reaction (Figure 2e). Taken together, these results
demonstrate that the IGF-I and IGFBP-3 circulating
levels at disease diagnosis were significantly higher in
the LL patients who developed ENL than among the LL
patients who did not experience reaction during MDT.
In the course of ENL episodes, however, these levels
tended to decrease, attaining levels similar to those
found among the NR LL patients.
Circulating IGF-I and IGFBP-3 levels before and during RR
episodes
Next, the IGF-I and IGFBP-3 levels in the context of
RR episodes, another frequent type of acute inflamma-
tory episode in leprosy, were investigated. Type 1 reac-
tion, or RR, more common among BL patients, affects
approximately one-third of these patients, especially in
the first year of MDT [22]. For this reason, a group of
BL who underwent RR episodes during MDT (referred
to as R BL; n = 25) was included in this analysis.
Serum samples were obtained at 2 different time
points in R BL patients: i) at the onset of MDT, when
no signs of reaction were detected (referred to as R
BLt=0 ); and ii) during reaction (referred to as R BLRR)
occurring between 2 weeks and 18 months after the
beginning of treatment (mean average of 6.6 ± 4.8
months).
As a first step, circulating levels of IGF-I and IGFBP-3
in R BL vs. NR BL patients at disease diagnosis were
compared. In contrast to the differences observed for LL
patients in the context of ENL, similar levels of IGF-I
and IGFBP-3 were detected in NR BL and R BL patients
(Figure 3a; data not shown). The next step involved
measuring the levels of IGF-I and IGFBP-3 before and
during RR episodes in R BL patients (n = 15). Curiously,
in contrast to the decreasing levels observed during
ENL, IGF-I levels significantly increased during RR (P <
0.05), as shown by the individual behavior of each
patient displayed in Figure 3b. However, no significant
alterations were observed in IGFBP-3 and TNF-a levels
during RR (data not shown).
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Figure 2 Circulating IGF-I and IGFBP-3 levels change according to disease status in LL patients. Box-plots represent the serum levels of
IGF-I (a) and IGFBP-3 (b) assessed in nonreactional (NR LL) and reactional LL (R LLt=0 ) patients at the pre-MDT stage. Median values are
indicated by lines (-). (c), (d) and (e) represent the serum levels of IGF-I, IGFBP-3, and TNF-a, respectively, at the pre-MDT stage and during ENL
(R LLENL). Each line represents one patient. Paired t test was used for statistical analysis.
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The interplay between the immune and neuroendocrine
systems exerts a critical role in the maintenance of host
homeostasis during infection. The neuroendocrine sys-
tem not only favors the building of an effective immune
response against the pathogen, but also controls its
intensity, thus avoiding extensive tissue damage [7].
Leprosy is an infectious disease with a strong immune-
inflammatory component, whose status dictates both the
clinical form of the disease as well as the occurrence of
reactional episodes. This particular characteristic makes
this disease an especially attractive model for studying
neuroimmunoendocrine interactions in that it allows for
a broader understanding of the interplay among hor-
mones, cytokines, and GCs during chronic inflammation
in combination with acute inflammatory episodes in
response to mycobacterial antigens. One of the many
players involved in this interaction is the hormone IGF-
I, previously shown to suffer a serious imbalance during
infectious and inflammatory diseases [7,9]. In the pre-
sent study, for the first time the IGF system was ana-
lyzed during the course of leprosy. Analysis was done by
measuring the circulating levels of IGF-I and IGFBP-3
in patients representing status variations in the
immune-inflammatory response to ML infection.
Circulating IGF-I/IGFBP-3 was initially examined
across the leprosy spectrum. Interestingly, while no sig-
nificant difference was observed between BT patients
and HC, both the nonreactional BL and LL (multibacil-
lary) patients showed low levels of IGF-I/IGFBP-3. It is
worth noting that the IGF-I/IGFBP-3 levels across the
leprosy spectrum appeared to follow a trend similar to
the one observed with respect to serum IFN-g [23,24]
(higher at the tuberculoid pole) but contrary to what
was found regarding the circulating levels of the pro-
inflammatory cytokines IL-1-b, IL-6, and TNF-a (higher
at the LL pole) [19,20]. Moreover, recovery of IGF-I
levels after treatment suggests that the low levels
observed in these patients resulted from a direct down
modulation by ML infection.
The low circulating levels of IGF-I/IGFBP-3 found in
nonreactional LL patients (~75% with below-normal
levels) were in parallel with those found in other critical
illnesses like sepsis [25,26]. It is known that the inflam-
matory response to sepsis is followed by the develop-
ment of a hypo-inflammatory and impaired immune
response, which is unable to eradicate the infection [27].
The low IGF-I/IGFBP-3 levels found in the chronic
p h a s eo fs e p s i sa r et h er e s u l to fo v e r a c t i v a t i o no ft h e
hypothalamic-pituitary-adrenal (HPA) axis by the exces-
sive and prolonged production of pro-inflammatory
cytokines, leading to the subsequent peripheral secretion
of GCs and inhibition of IGF synthesis by the liver [7].
Interestingly, in tuberculosis, another mycobacterial dis-
ease, no alterations in circulating IGF-I levels were
observed when patients with different degrees of pul-
monary involvement and healthy controls were com-
pared [28].
LL patients and sepsis share this immunosuppressive
state. In polar LL patients, the absence of a CMI
response against ML allows the pathogen to proliferate
indiscriminately, reach high numbers, and disseminate
systemically throughout the bloodstream. Although pre-
senting high bacteremia, approximately 50% of LL
patients are clinically stable, which can be considered
clear evidence of a controlled, finely-regulated immune-
inflammatory response due to the activation of anti-
inflammatory loops that prevent over-inflammation and
subsequent immune-mediated tissue damage. It is,
therefore, reasonable to speculate that the HPA axis,
assumed to be the main physiological feedback loop in
inflammation, is activated in these patients, playing a
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Figure 3 Circulating IGF-I and IGFBP-3 levels change according to disease status in BL patients. a. The box-plot represents the serum
levels of IGF-I assessed in nonreactional (NR BL) and reactional BL (R BLt=0 ) patients at the pre-MDT stage. Median values are indicated by lines
(-). b. Represent the serum levels of IGF-I at the pre-MDT stage and during RR (R BLRR). Each line represents one patient. Paired t test was used
for statistical analysis.
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Page 6 of 8critical role in maintaining homeostasis. HPA axis acti-
vation in LL patients is expected, based on the high cir-
culating levels of the pro-inflammatory cytokines
detected such as IL-1b,I L - 6 ,a n dT N F - a [19,20]. To
date, however, data concerning the circulating levels of
cortisol and the adrenal functional status in leprosy have
been conflicting [13]. Moreover, intrinsic anti-inflamma-
tory mechanisms such as the high production of IL-10
observed in these patients [29] may complement the
immune-suppressive effects of GCs, making possible a
controlled immune-inflammatory response in a scenario
of hyper-stimulation of the host immune system result-
ing from accumulated concentrations of mycobacterial
antigens.
It is noteworthy that the LL patients who had ENL
during treatment showed significantly higher levels of
IGF-I/IGFBP-3 at the pre-MDT stage (up to 2 years
before reaction), suggesting that changes in these pro-
teins may reflect the delicate balance between the pro-
and anti-inflammatory responses in these patients and,
consequently, the risk of initiating an uncontrollable
inflammatory event. Again, in these patients, the higher
IGF-I/IGFBP-3 levels found among R LL patients may
be the result of insufficient anti-inflammatory feedback,
necessary for the maintenance of homeostasis in the
presence of high concentrations of ML antigens. While
lower levels of IGF-I/IGFBP-3 might be reflective of
high immune-suppression levels, a controlled immune-
inflammatory response, and high clinical stability in NR
LL patients, higher levels of this hormone in R LL
patients might indicate reduction of suppression and
ENL development.
Our results are consistent with previous data indicat-
ing high systemic production of TNF-a during ENL
[19]. Also observed was a reduction in IGF-I/IGFBP-3
levels during ENL. This finding could be interpreted as
an attempt to reach the low levels observed in NR LL,
most likely the result of the activation of an anti-inflam-
matory loop such as the release of GCs in response to
the presence of high levels of pro-inflammatory cyto-
kines produced during reaction.
It should be highlighted that whenever a group of BL
patients was analyzed, interesting but opposing findings
were observed according to the immunological stability
of the patients in the context of changes in circulating
IGF-I/IGFBP-3. In contrast to the LL group undergoing
or not ENL, no differences in circulating IGF-I/IGFBP-3
between nonreactional vs. reactional BL (who underwent
RR during treatment) at the time of diagnosis were
observed. Moreover, in contrast to ENL, during RR, an
increase in IGF-I/IGFBP-3 was demonstrated while, con-
sistent with previous data [30,31], no changes in the
TNF-a serum levels were detected. Differently from LL
patients, however, BL patients are known to build a
weak CMI response against ML [23,24]; and RR is char-
acterized by an increase in the Th1 response to ML
antigens, which is capable of rapidly triggering nerve
damage [32]. Based on the capacity of IGF-I to stimulate
the secretion of IL-10 by activated T cells [16], it is
tempting to speculate an anti-inflammatory role for this
hormone in BL patients by its ability to dampen local
inflammation in the skin and nerves in nonreactional
patients and during RR. Thus, increased IGF-I levels
during RR could be interpreted as an attempt to re-
establish homeostasis.
In conclusion, our data revealed important alterations
in the IGF system in relation to the status of the host
immune-inflammatory response to ML. These findings
support the hypothesis that interactions between the
immune and neuroendocrine systems play a critical role
during the natural course of ML infection, contributing
to a controlled immune-inflammatory response across
the spectral clinical forms of leprosy. Disruption of
immune neuroendocrine homeostasis seems to be asso-
ciated with acute, uncontrolled inflammatory episodes.
Of note, our data indicate that circulating IGF-I and
IGFBP-3 levels can be reliably used as predictive bio-
markers for ENL at diagnosis, favoring the development
of new strategies for the management of leprosy patients
and the prevention of reaction and neuropathy.
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